DelveInsight’s, “Spleen Tyrosine Kinase (SYK) Inhibitors Pipeline Insight, 2025,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Spleen Tyrosine Kinase (SYK) Inhibitors pipeline landscape. It covers the SYK Inhibitor pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the SYK Inhibitor Treatment Landscape @ SYK Inhibitor Pipeline Outlook

Key Takeaways from the SYK Inhibitor Pipeline Report

• DelveInsight’s SYK Inhibitor pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for SYK Inhibitor treatment.
• The leading SYK Inhibitor Companies such as Genosco, Portola Pharmaceuticals, GlaxoSmithKline, FUJIFILM Corporation, TopiVert, Takeda Oncology, Asana BioSciences and others.
• Promising SYK Inhibitor Pipeline Therapies such as SKI-O-703, Entospletinib and others.

Stay informed about the cutting-edge advancements in SYK Inhibitor treatments. Download for updates and be a part of the revolution @ SYK Inhibitor Clinical Trials Assessment

SYK Inhibitor Emerging Drugs Profile

• Cevidoplenib dimesylate: Genosco

The dimesylate salt of cevidoplenib, an orally available inhibitor of spleen tyrosine kinase (SYK), with potential anti-inflammatory and immunomodulating activities. Upon oral administration, cevidoplenib binds to and inhibits the activity of SYK, blocking Fc receptor and B-cell receptor (BCR)-mediated signaling in inflammatory cells, including macrophages, neutrophils, mast cells, natural killer (NK) cells and B cells. This leads to the inhibition of the activation of these inflammatory cells, and the related inflammatory responses and tissue damage.

• HMPL-523: Hutchison MediPharma

An orally available inhibitor of spleen tyrosine kinase (Syk), with potential immune-modulating and antineoplastic activities. Upon oral administration of Syk inhibitor HMPL-523, this agent binds to and inhibits the activity of Syk. This inhibits B-cell receptor (BCR) signaling, which leads to the inhibition of B-cell activation, and prevents tumor cell activation, migration, adhesion and proliferation.

The SYK Inhibitor Pipeline Report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of SYK Inhibitor with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for SYK Inhibitor Treatment.
• SYK Inhibitor Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• SYK Inhibitor Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the SYK Inhibitor market.

Learn more about SYK Inhibitor Drugs opportunities in our groundbreaking SYK Inhibitor research and development projects @ SYK Inhibitor Unmet Needs

SYK Inhibitor Companies

Genosco, Portola Pharmaceuticals, GlaxoSmithKline, FUJIFILM Corporation, TopiVert, Takeda Oncology, Asana BioSciences and others.

Spleen Tyrosine Kinase (SYK) Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Molecule Type

SYK Inhibitor Products have been categorized under various Molecule types such as

• Monoclonal antibodies
• Small molecules
• Product Type

Stay informed about how we’re transforming the future of SYK landscape @ SYK Inhibitor Market Drivers and Barriers, and Future Perspectives

Scope of the SYK Inhibitor Pipeline Report

• Coverage- Global
• SYK Inhibitor Companies- Genosco, Portola Pharmaceuticals, GlaxoSmithKline, FUJIFILM Corporation, TopiVert, Takeda Oncology, Asana BioSciences and others.
• SYK Inhibitor Pipeline Therapies- SKI-O-703, Entospletinib and others.
• SYK Inhibitor Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• SYK Inhibitor Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of SYK Inhibitor Pipeline on our website @ SYK Inhibitor Emerging Drugs and Companies

Table of Content

1. Introduction
2. Executive Summary
3. Spleen Tyrosine Kinase (SYK) Inhibitors: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Spleen Tyrosine Kinase (SYK) Inhibitors – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Spleen Tyrosine Kinase (SYK) Inhibitors Collaboration Deals
9. Late Stage Products (Phase II/III)
10. TOP 1630: TopiVert
11. Mid Stage Products (Phase II)
12. Cevidoplenib: Genosco
13. PRT 2761: Portola Pharmaceuticals
14. Early Stage Products (Phase I/II)
15. Gusacitinib: Asana BioSciences
16. Early Stage Products (Phase I)
17. Mivavotinib: Takeda Oncology
18. Pre-clinical and Discovery Stage Products
19. Research programme: small molecule therapeutics: Genosco
20. Inactive Products
21. Comparative Analysis
22. Spleen Tyrosine Kinase (SYK) Inhibitors- Market Drivers and Barriers
23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/spleen-tyrosine-kinase-syk-inhibitors-pipeline-insight